Loading...
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer
SUMMARY: In women with estrogen receptor(ER)- and ErbB2 (HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance. As such, co-targeting ErbB1 and ErbB2 with la...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
S. Karger GmbH
2010
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2931095/ https://ncbi.nlm.nih.gov/pubmed/20847831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000285775 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|